UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma

The New England journal of medicine, 2020-09, Vol.383 (12), p.1139-1148

2020

Volltextzugriff (PDF)

KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma

Journal for immunotherapy of cancer, 2020-12, Vol.8 (2), p.e001806

2020

Volltextzugriff (PDF)

Abstract CT025: Dabrafenib plus trametinib in BRAF V600E-mutant high-grade (HGG) and low-grade glioma (LGG)

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.CT025-CT025

2021

Volltextzugriff (PDF)

Spartalizumab or placebo in combination with dabrafenib and trametinib in patients with BRAF V600-mutant melanoma: exploratory biomarker analyses from a randomized phase 3 trial (COMBI-i)

Journal for immunotherapy of cancer, 2022-06, Vol.10 (6), p.e004226

2022

Volltextzugriff (PDF)

Oncolytic immunotherapy: unlocking the potential of viruses to help target cancer

Cancer Immunology, Immunotherapy, 2017-10, Vol.66 (10), p.1249-1264

2017

Volltextzugriff (PDF)

Efficacy and Safety of Dabrafenib in Pediatric Patients with BRAF V600 Mutation-Positive Relapsed or Refractory Low-Grade Glioma: Results from a Phase I/IIa Study

Clinical cancer research, 2019-12, Vol.25 (24), p.7303-7311

2019

Volltextzugriff (PDF)

Phase 2 Study of Dabrafenib Plus Trametinib in Patients With BRAF V600E-Mutant Metastatic NSCLC: Updated 5-Year Survival Rates and Genomic Analysis

Journal of thoracic oncology, 2022-01, Vol.17 (1), p.103-115

2022

Volltextzugriff (PDF)

LGG-49. SAFETY AND EFFICACY OF TRAMETINIB (T) MONOTHERAPY AND DABRAFENIB + TRAMETINIB (D+T) COMBINATION THERAPY IN PEDIATRIC PATIENTS WITH BRAF V600-MUTANT LOW-GRADE GLIOMA (LGG)

Neuro-oncology (Charlottesville, Va.), 2020-12, Vol.22 (Suppl 3), p.iii375-iii375

2020

Volltextzugriff (PDF)

Estimation of Distant Metastasis-free Survival in Trials of Adjuvant Therapy for Melanoma. Reply

The New England journal of medicine, 2019-04, Vol.380 (14), p.1376-1377

2019

Volltextzugriff (PDF)

Dabrafenib plus trametinib in patients with relapsed/refractory BRAF V600E mutation–positive hairy cell leukemia

Blood, 2023-03, Vol.141 (9), p.996-1006

2023

Volltextzugriff (PDF)

ACTR-30. UPDATED EFFICACY AND SAFETY OF DABRAFENIB PLUS TRAMETINIB IN PATIENTS WITH RECURRENT/REFRACTORY BRAF V600E–MUTATED HIGH-GRADE GLIOMA (HGG) AND LOW-GRADE GLIOMA (LGG)

Neuro-oncology (Charlottesville, Va.), 2019-11, Vol.21 (Suppl 6), p.vi19-vi20

2019

Volltextzugriff (PDF)

Estimation of Distant Metastasis–free Survival in Trials of Adjuvant Therapy for Melanoma

The New England journal of medicine, 2019-04, Vol.380 (14), p.1374-1377

2019

Volltextzugriff (PDF)

BRAF -Mutant Transcriptional Subtypes Predict Outcome of Combined BRAF, MEK, and EGFR Blockade with Dabrafenib, Trametinib, and Panitumumab in Patients with Colorectal Cancer

Clinical cancer research, 2020-06, Vol.26 (11), p.2466-2476

2020

Volltextzugriff (PDF)

Did patients (pts) in OPTiM, a trial of unresectable melanoma, have truly unresectable disease?: Results from an independent review

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.e20109-e20109

2015

Volltextzugriff (PDF)

Administration and Handling of Talimogene Laherparepvec: An Intralesional Oncolytic Immunotherapy for Melanoma

Oncology nursing forum, 2016-03, Vol.43 (2), p.219-226

2016

Volltextzugriff (PDF)

Dabrafenib + trametinib combination therapy in pediatric patients with BRAF V600-mutant low-grade glioma: Safety and efficacy results

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.10506-10506

2020

Volltextzugriff (PDF)

The anti–PD-1 antibody spartalizumab in combination with dabrafenib and trametinib in advanced BRAF V600–mutant melanoma: Efficacy and safety findings from parts 1 and 2 of the Phase III COMBI-i trial

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.10028-10028

2020

Volltextzugriff (PDF)

Abstract CT120: A randomized, open-label, open-platform, Phase II study evaluating the efficacy and safety of novel spartalizumab (PDR001) combinations in previously treated unresectable or metastatic melanoma (PLATforM)

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.CT120-CT120

2019

Volltextzugriff (PDF)

LGG-49. SAFETY AND EFFICACY OF TRAMETINIB (T) MONOTHERAPY AND DABRAFENIB + TRAMETINIB (D+T) COMBINATION THERAPY IN PEDIATRIC PATIENTS WITH BRAF V600-MUTANT LOW-GRADE GLIOMA (LGG)

Neuro-oncology (Charlottesville, Va.), 2020-12, Vol.22 (Supplement_3), p.iii375-iii375

2020

Volltextzugriff (PDF)

Circulating tumor DNA (ctDNA) kinetics to predict survival in patients (pts) with unresectable or metastatic melanoma treated with dabrafenib (D) or D + trametinib (T)

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.9510-9510

2019

Volltextzugriff (PDF)

Long-term benefit of adjuvant dabrafenib + trametinib (D+T) in patients (pts) with resected stage III BRAF V600–mutant melanoma: Five-year analysis of COMBI-AD

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.10001-10001

2020

Volltextzugriff (PDF)

Updated overall survival (OS) and genomic analysis from a single-arm phase II study of dabrafenib (D) + trametinib (T) in patients (pts) with BRAF V600E mutant (Mut) metastatic non-small cell lung cancer (NSCLC)

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.9593-9593

2020

Volltextzugriff (PDF)

Effect of first-line spartalizumab + dabrafenib + trametinib on immunosuppressive features detected in peripheral blood and clinical outcome in patients (pts) with advanced BRAF V600–mutant melanoma

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.10034-10034

2020

Volltextzugriff (PDF)

Tumor microenvironment (TME), longitudinal biomarker changes, and clinical outcome in patients (pts) with advanced BRAF V600–mutant melanoma treated with first-line spartalizumab (S) + dabrafenib (D) + trametinib (T)

Journal of clinical oncology, 2020-02, Vol.38 (5_suppl), p.39-39

2020

Volltextzugriff (PDF)

The anti–PD-1 antibody spartalizumab (S) in combination with dabrafenib (D) and trametinib (T) in previously untreated patients (pts) with advanced BRAF V600–mutant melanoma: Updated efficacy and safety from parts 1 and 2 of COMBI-I

Journal of clinical oncology, 2020-02, Vol.38 (5_suppl), p.57-57

2020

Volltextzugriff (PDF)

1 – 25 von 39

Suche als RSS-Feed

Aktive Filter

KollektionIngentaConnect

ThemaMelanoma - Drug Therapy

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(39)
Mit Volltextzugriff
(37)

Publikationsform

Artikel
(39)

Sprache

Englisch
(39)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(10)
Science & Technology
(10)
Humans
(7)
Melanoma
(7)
Oncology
(7)
Immunotherapy
(5)
Targeted Cancer Therapy
(5)
Cancer
(4)
Metastasis
(4)
Mutation
(4)
Metastases
(3)
Monoclonal Antibodies
(3)
Patients
(3)
Proto-Oncogene Proteins B-Raf - Genetics
(3)
Anemia
(2)
Anemia - Drug Therapy
(2)
Antineoplastic Agents - Adverse Effects
(2)
Antineoplastic Agents - Therapeutic Use
(2)
Cancer Research
(2)
Clinical Trials
(2)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma

KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma

Abstract CT025: Dabrafenib plus trametinib in BRAF V600E-mutant high-grade (HGG) and low-grade glioma (LGG)

Spartalizumab or placebo in combination with dabrafenib and trametinib in patients with BRAF V600-mutant melanoma: exploratory biomarker analyses from a randomized phase 3 trial (COMBI-i)

Oncolytic immunotherapy: unlocking the potential of viruses to help target cancer

Efficacy and Safety of Dabrafenib in Pediatric Patients with BRAF V600 Mutation-Positive Relapsed or Refractory Low-Grade Glioma: Results from a Phase I/IIa Study

Phase 2 Study of Dabrafenib Plus Trametinib in Patients With BRAF V600E-Mutant Metastatic NSCLC: Updated 5-Year Survival Rates and Genomic Analysis

LGG-49. SAFETY AND EFFICACY OF TRAMETINIB (T) MONOTHERAPY AND DABRAFENIB + TRAMETINIB (D+T) COMBINATION THERAPY IN PEDIATRIC PATIENTS WITH BRAF V600-MUTANT LOW-GRADE GLIOMA (LGG)

Estimation of Distant Metastasis-free Survival in Trials of Adjuvant Therapy for Melanoma. Reply

Dabrafenib plus trametinib in patients with relapsed/refractory BRAF V600E mutation–positive hairy cell leukemia

ACTR-30. UPDATED EFFICACY AND SAFETY OF DABRAFENIB PLUS TRAMETINIB IN PATIENTS WITH RECURRENT/REFRACTORY BRAF V600E–MUTATED HIGH-GRADE GLIOMA (HGG) AND LOW-GRADE GLIOMA (LGG)

Estimation of Distant Metastasis–free Survival in Trials of Adjuvant Therapy for Melanoma

BRAF -Mutant Transcriptional Subtypes Predict Outcome of Combined BRAF, MEK, and EGFR Blockade with Dabrafenib, Trametinib, and Panitumumab in Patients with Colorectal Cancer

Did patients (pts) in OPTiM, a trial of unresectable melanoma, have truly unresectable disease?: Results from an independent review

Administration and Handling of Talimogene Laherparepvec: An Intralesional Oncolytic Immunotherapy for Melanoma

Dabrafenib + trametinib combination therapy in pediatric patients with BRAF V600-mutant low-grade glioma: Safety and efficacy results

The anti–PD-1 antibody spartalizumab in combination with dabrafenib and trametinib in advanced BRAF V600–mutant melanoma: Efficacy and safety findings from parts 1 and 2 of the Phase III COMBI-i trial

Abstract CT120: A randomized, open-label, open-platform, Phase II study evaluating the efficacy and safety of novel spartalizumab (PDR001) combinations in previously treated unresectable or metastatic melanoma (PLATforM)

LGG-49. SAFETY AND EFFICACY OF TRAMETINIB (T) MONOTHERAPY AND DABRAFENIB + TRAMETINIB (D+T) COMBINATION THERAPY IN PEDIATRIC PATIENTS WITH BRAF V600-MUTANT LOW-GRADE GLIOMA (LGG)

Circulating tumor DNA (ctDNA) kinetics to predict survival in patients (pts) with unresectable or metastatic melanoma treated with dabrafenib (D) or D + trametinib (T)

Long-term benefit of adjuvant dabrafenib + trametinib (D+T) in patients (pts) with resected stage III BRAF V600–mutant melanoma: Five-year analysis of COMBI-AD

Updated overall survival (OS) and genomic analysis from a single-arm phase II study of dabrafenib (D) + trametinib (T) in patients (pts) with BRAF V600E mutant (Mut) metastatic non-small cell lung cancer (NSCLC)

Effect of first-line spartalizumab + dabrafenib + trametinib on immunosuppressive features detected in peripheral blood and clinical outcome in patients (pts) with advanced BRAF V600–mutant melanoma

Tumor microenvironment (TME), longitudinal biomarker changes, and clinical outcome in patients (pts) with advanced BRAF V600–mutant melanoma treated with first-line spartalizumab (S) + dabrafenib (D) + trametinib (T)

The anti–PD-1 antibody spartalizumab (S) in combination with dabrafenib (D) and trametinib (T) in previously untreated patients (pts) with advanced BRAF V600–mutant melanoma: Updated efficacy and safety from parts 1 and 2 of COMBI-I

Aktive Filter

Suchergebnisse filtern